NextCure (NXTC)
Developing antibody-drug conjugate candidates for difficult-to-treat cancers.
$7.35
Pre-market−0.05 (−0.68%)
At close$7.40(+8.82%)
Something off on this page? Send us feedback.
Next report
Nov 4, 2026
estimated · in 62 days
EPS estimate
−$0.90
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$4.92−$4.68−$11.29−$3.22−$0.81−$1.87−$2.80Pending
Estimate−$4.08−$4.80−$4.62−$4.06−$2.26−$1.81−$1.95−$0.90
Surprise−20.6%+2.5%−144.4%+20.7%+64.2%−3.3%−43.6%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported———————Pending
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.90 | — | — |
| Aug 2026 | −$1.95 | −$2.80 | −43.6% |
| May 2026 | −$1.81 | −$1.87 | −3.3% |
| Mar 2026 | −$2.26 | −$0.81 | +64.2% |
| Nov 2025 | −$4.06 | −$3.22 | +20.7% |
The latest year is open to everyone — the 30 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| Jun 2019 | |||
| Dec 2018 | |||
| Sep 2018 | |||
| Jun 2018 | |||
| Mar 2018 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | −$0.90 | — | — | — | — | — | — |
| Aug 6, 2026 | −$1.95 | −$2.80 | −43.6% | — | — | — | +4.5% |
| May 7, 2026 | −$1.81 | −$1.87 | −3.3% | — | — | — | −4.1% |
| Mar 5, 2026 | −$2.26 | −$0.81 | +64.2% | — | — | — | −2.9% |
| Nov 5, 2025 | −$4.06 | −$3.22 | +20.7% | — | — | — | +2.0% |
The latest year is open to everyone — the 30 quarters behind it read with an account. Sign in | |||||||
| Aug 7, 2025 | |||||||
| May 1, 2025 | |||||||
| Mar 6, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 1, 2024 | |||||||
| May 2, 2024 | |||||||
| Mar 21, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 4, 2023 | |||||||
| Mar 2, 2023 | |||||||
| Nov 3, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 5, 2022 | |||||||
| Mar 3, 2022 | |||||||
| Nov 4, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 6, 2021 | |||||||
| Mar 4, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 12, 2020 | |||||||
| Nov 12, 2019 | |||||||
| Aug 12, 2019 | |||||||
| Jun 10, 2019 | |||||||
| Dec 31, 2018 | |||||||
| Sep 30, 2018 | |||||||
| Jun 30, 2018 | |||||||
| Mar 31, 2018 | |||||||